Researchers in the study analyzed records of 231 patients who reported experiencing pain during chemotherapy. The patients were randomly assigned to two groups in the five-week study: one received Cymbalta while the other received a placebo. After five weeks of treatment, 59 percent of patients taking Cymbalta reported reduced pain, compared to 39 percent of patients taking the placebo.
“The drug doesn’t work in everyone,” said study author Ellen M. Lavoie Smith. “The good news is it worked in the majority of patients. We need to figure out who are the responders. If we can predict who they are, we can target the treatment to the people it’s going to work for.”
Related Articles on Pain Management:
Exercise Can Reduce Nerve Pain, Study Says
New Tennessee Law Requires Physicians to Use Drug Monitoring Database
4 Steps to Greater Collaboration Between Pain Management & Primary Care
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
